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ABSTRACT
Purpose To study the effect of several operative parameters,
particularly pH and salt concentration, on the stability and
aggregation kinetics of IgG solutions under the conditions
typically encountered in downstream processing.
Methods The time evolution of the aggregates is analyzed by
a combination of dynamic light scattering, size exclusion
chromatography (SEC) and field flow fractionation (FFF).
Secondary structure changes are monitored by circular
dichroism.
Results For the given antibody, it is found that at pH lower than
4.0 addition of salt induces a reversible aggregation to oligomers
accompanied by an increase in the content of the β-sheet
structure. The aggregation rate increases monotonically with the
salt concentration. Both the SEC and FFF techniques are
successfully applied to obtain the oligomer distributions, and their
results are consistent. The modified Lumry-Eyring kinetic model
can well describe the time evolutions of the oligomers.
Conclusions For the given antibody, low pH and presence of
salt induce conformational changes that are responsible for the
reversible aggregation, but in the investigated conditions only
small soluble oligomers are formed and oligomer sizes larger
than trimer are negligible. For this reason, no accompanied
macroscopic changes can be observed.
KEY WORDS aggregation . antibody . FFF. oligomer
distribution . SEC
INTRODUCTION
Thanks to increased understanding of the biological
background of various human diseases, protein drugs have
been increasingly developed and now occupy a significant
part of the whole pharmaceutical market (1). Particularly,
monoclonal antibodies represent the most rapidly growing
product inside the family of recombinant therapeutic
proteins (2). The successful commercialization of protein
drug is often limited by instability problems, which can be
both chemical (e.g., deamidation, oxidation, hydrolysis) and
physical (e.g., conformational changes, adsorption to
surfaces, aggregation) (3,4). Protein aggregation represents
the most common form of all possible deteriorations and
can basically be encountered in each step of the production
process (5). The spectrum of the possible products resulting
from aggregation is wide. The several types of aggregates
may be classified in covalent/non-covalent, reversible/
irreversible, native/denatured, soluble/non-soluble (6,7).
Obviously, protein aggregation in pharmaceutical prod-
ucts must be avoided, since it usually leads to inactivation of
the drug and can even trigger an immunogenic reaction of
the organism. Since the debate on the possible immunor-
esponse created by aggregates is still open (8,9), strict
specification limits are imposed by the drug manufacturers
as a precaution. Shelf-life prediction is a challenging
problem for pharmaceutical companies, since several
external factors may induce protein instability (4,7) during
production, storage, transportation and handling of the
pharmaceutical component: temperature (10), buffer for-
mulation (pH, presence of solutes, co-solvents, surfactants,
salts) (11), mechanical stress (12,13) and surface interaction
(14). Such environmental factors affect at a molecular level
the protein-protein and protein-salt interactions (15) with
consequences on the two main aspects involved in the
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aggregation process: the colloidal stability of the protein
solution and the thermodynamic folding of the protein (4).
The two processes are strictly connected one to another and
are often inseparable.
Protein aggregation is associated to more than 20 human
disorders (16), most of which are neurodegenerative
diseases like Prion diseases (17), Alzheimer’s disease,
Parkinson’s disease, sickle cell disease and Huntington’s
disease. Typically, in such biological systems proteins
aggregate into large insoluble fibrils through nucleation-
dependent assembly, even if in some cases also amorphous
deposits are observed. Although great attention has been
given in the literature to understand these diseases, the
mechanism leading to the formation of such fibrils is
unclear, and validated treatments are still missing. Achiev-
ing a better understanding of the mechanisms responsible
for protein aggregation is crucial for the development of an
effective pharmaceutical treatment of the aforementioned
diseases. While the mechanism leading to amyloid fibrils is
the object of large investigation in the literature, relatively
few papers have tried to elucidate the aggregation pathway
of monoclonal antibodies (18–20).
In this work, we focus on the aggregation of an IgG
immunoglobulin during its production process and specif-
ically on the downstream, i.e. the purification portion of it.
In particular, we investigate the conditions relevant for
Protein A chromatography, which represents the typical
capture process in antibodies purification (21). The effect of
several operating parameters (i.e., pH, protein concentra-
tion, buffer nature, concentration of salts) on the protein
solution stability is investigated. The main focus of this
work is on antibody oligomer formation and distribution.
Since each technique has its own limits and advantages and
often cannot be used alone to detect the aggregation
process (7,22), the oligomer formation and distribution
have been continuously followed on-line by dynamic light
scattering (DLS) and off-line by size exclusion chromatog-
raphy (SEC) and asymmetric field flow fractionation (FFF).
Circular dichroism (CD) studies were also performed to
correlate aggregation tendency with change in protein
secondary structure. Moreover, the comparison between
on-line and off-line data can give important information
about the reversibility of the aggregation. The obtained
oligomer information during aggregation is then modelled
in the frame of a modified Lumry-Eyring model (23–25),
which considers the native monomers to reversibly unfold
into a partially unfolded, aggregation-prone state (26).
The present work represents also a general procedure for
analyzing protein oligomers, which, produced in the early
stages of the aggregation, are considered to be crucial, toxic
species in many diseases (27). An example is represented by
the amyloidosis diseases related to aggregation of light
chains of antibodies (28). Since the size of the light chain
fragments is not much different from that of the complete
antibody and the two proteins share common character-
istics, the approach described in this work may be used to
detect light chain oligomers during aggregation.
MATERIALS AND METHODS
Antibodies and Chemicals
The monoclonal IgG antibody employed in this work is an
IgG 2, with MW ~150 kDa and the isoelectric point (pI)
between 7.35 and 8.15, supplied by Merck Serono (Vevey,
Switzerland).
The buffers used for all experiments were a 25 mM citric
acid solution and a 25 mM acetic acid solution, both at
pH 3.0. In order to prevent formation and proliferation of
bacteria during storage, 1.0 g/L of sodium azide was added to
the buffers. All buffers were filtered with 0.45 μm cut-off,
Durapore membrane filters (Millipore, Billerica, MA, USA).
Dynamic Light Scattering
The average size of the aggregates or oligomers was
measured on-line by the in-situ dynamic light scattering
(DLS) technique, using a Zetasizer Nano (Malvern, UK).
The original antibody concentration was 12 g/L, which was
then diluted to 1 g/L by a selected buffer solution with
proper pH and ionic strength to monitor formation of the
oligomers. All samples were filtered with a 0.02 μm cut-off,
Anotop 10 syringe filter (Whatman, Kent, UK), before
starting the aggregation. Micro UV-Cuvettes with dimen-
sion 12.5×12.5×45 mm (70 μL) and light path 1 cm
(Brand GmbH, Wertheim, Germany) were used for the
DLS measurements. For each investigated condition, three
independent samples were prepared and analyzed. For a
single sample, the size at a given time is the repetition of
three measurements. The reported values are the average
of the three independent experiments.
Size Exclusion Chromatography
During the DLS experiments, samples were taken and
analyzed by the size exclusion chromatography (SEC)
technique with a Superdex 200 10/300 GL, 10 mm×
300 mm size-exclusion column (GE Healthcare, Uppsala,
Sweden) assembled on a Agilent 1200 series HPLC unit
(Santa Clara, CA, USA) consisting of a quaternary pump
with degasser, an autosampler with a cooling unit, a
column oven, and a DAD detector. Each sample was
eluted for 60 min at a constant flow rate of 0.5 mL/min
using as mobile phase a 100 mM sodium sulphate, 25 mM
Na2HPO4 solution at pH 7.0, filtered with a 0.45 μm cut-
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off, Durapore membrane filter (Millipore, Billerica, MA,
USA). The UV absorbance peaks were detected at 280 nm
and 220 nm.
Field Flow Fractionations
Paralleling with the SEC technique, the field flow fractio-
nations (FFF) technique was also used to analyze the
oligomer composition. The applied instrument was an
AF4 Eclipse 3+ (Wyatt, Santa Barbara, CA, USA), coupled
with a 1200 Series isocratic pump from Agilent (Santa
Clara, CA, USA). A 275 mm LC channel for aqueous
solvents was used for Eclipse 3, with a trapezoidal spacer
(350 μm thick, 26.5 cm long) and a Nadir reg. cellulose
membrane with 10 kDa cut-off at the bottom (Wyatt,
Dernbach, Germany). The detector flow was set constant at
1 mL/min, and a step gradient of cross flow from 5 ml/min
to 0 ml/min was applied after 30 min (29). Twenty five
mM citric acid solution at pH 3.0 was used as mobile
phase, after filtration through a 0.1 μm cur-off, Durapore
membrane filter (Millipore, Billerica, MA, USA).
Circular Dichroism (CD)
For the variations in the secondary structure of the
antibody during aggregation, we have monitored the Far-
UV circular dichroism (CD) spectra of the same antibody
solutions using a Jasco-815 CD spectrophotometer (Mary’s
Court, Easton, MD) with the temperature of the cell holder
controlled at 25°C. A quartz cuvette with 0.1 cm path
length was used.
RESULTS
pH Effect
As already mentioned in the Introduction, protein A affinity
chromatography is commonly used as the capture step for
purification of monoclonal antibodies and Fc fusion
proteins in drug industry. The recovery of the product
bound to the stationary phase requires the elution with a
low pH mobile phase (usually between pH 3.0 and 4.0) (21),
which is well known to potentially induce aggregation (19).
Particularly, low pH values can lead to changes in the
structure of the Fc domain, while Fab fragments have been
shown to be more sensitive to temperature variations (30).
Moreover, highly concentrated antibody solutions, which
are desired for the economy of large-scale purification
processes, further increase the risk of inducing aggregation
under low pH conditions. The effect of pH was first
investigated for a solution of 1 g/L mAb in 25 mM citric
acid buffer with 0.15 M NaCl (a buffer commonly used in
protein A chromatography) at several pH values. The
stability of such solutions was followed on-line by in-situ
DLS. The time evolution of the average hydrodynamic
radius 〈Rh〉 of the distribution of mAb monomers and
oligomers is shown in Fig. 1a. For pH values between 4.5
and 6.0, the solutions are very stable (〈Rh〉=6 nm is in fact
the value corresponding to the monomer mAb under
examination), while aggregation occurs when pH drops
below a critical value of about 4.0. It is worth noting that
the extent of the aggregation in all cases is independent
of pH.
Moreover, for all cases where aggregation occurs, the
aggregation starts immediately after incubation without any
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Fig. 1 (a) Time evolutions of the average hydrodynamic radius 〈Rh〉,
measured on-line by in-situ DLS, for the 1 g/L mAb solution in 25 mM
citric acid buffer with 0.15 M NaCl, at pH 3.0 (●), 3.5 (□), 4.0 (>), 4.5 (■)
and pH 6 (○); (b) the same as (a) but for the 1 g/L mAb solution in
25 mM phospate buffer (○), 25 mM citric acid buffer (>) and 25 mM acetic
acid buffer (□) with 0.15 M NaCl at pH 3.0.
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lag-time, which is commonly encountered in other protein
aggregating systems. From the average 〈Rh〉 values shown in
Fig. 1a, only small oligomers are produced (probably no
more than 2 or 3 monomer units) and basically stop growing
after about 1.5 h. No macroscopic changes in the solutions
can in fact be observed even after 1 month of incubation.
Buffer and Salt Concentration Effect
To observe the effect of the ionic strength and the nature of
the buffer on the mAb aggregation, several experiments at
different salt concentrations and in different buffers
(phosphate, citric acid and acetic acid buffer), but at a
constant pH 3.0, were performed. The conditions for all the
experimental runs are described in Table I.
The stability of the mAb solutions in the concentration
range from 1 to 5 g/L was first checked in various buffers,
typically used in protein A chromatography, without add-
ing additional salts (runs 1 to 4 in Table I). All antibody
solutions were stable after 4 weeks, with an average
hydrodynamic radius of around 6 nm, which depends
slightly on the type of buffer.
The addition of sodium chloride to different buffers
leads to different consequences. Figure 1b shows the time
evolution of 〈Rh〉 for 1 g/L mAb solutions at 0.15 M
sodium chloride in three different buffers. In the case of
phosphate buffer, the antibody solution remains stable for
more than 3 weeks, while in acetate and citric acid buffers
aggregation occurs with very similar kinetics and extent.
Next, for the acetic and citric acid buffers, the effect of the
NaCl concentration on mAb aggregation has been investi-
gated in a large range of NaCl concentrations between 0
and 0.5 M. Figure 2 shows the time evolutions of 〈Rh〉 for
the mAb solutions in the citric acid buffer at different salt
concentrations (runs 4, 5, 6, 9 and 10 in Table I), and the
corresponding CD spectra after 24 h of incubation are
shown in Fig. 3a. It can be seen that as the salt
concentration increases, the aggregation extent increases,
and the minimum (at 217 nm) in the CD spectra,
corresponding to the β-sheet structure of the immunoglob-
ulin (30), moves downwards more and more, indicating that
the aggregation is accompanied by an increase in the more
ordered β-sheet structure content.
In the case of 0.3 M NaCl in Fig. 2 (run 6 in Table I),
the corresponding time evolution of the CD spectra has also
been measured and shown in Fig. 3b. It is evident that the
minimum in the CD spectra moves progressively down-
wards with time. However, after a few hours, the change in
the spectra for different times (e.g., at 22 h and 48 h)
becomes insignificant. This is consistent with the aggrega-
Run mAb Conc. (g/L) Buffer NaCl Conc. mol/L Stability
1 1 to 5 25 mM Phosphate 0 Stable
2 1 to 5 0.1 M Glycine-HCl 0 Stable
3 1 to 5 25 mM-1 M Acetic Acid 0 Stable
4 1 to 5 25 mM Citric Acid 0 Stable
5 1 25 mM Citric Acid 0.1 Unstable
6 1 25 mM Citric Acid 0.15 Unstable
7 10 25 mM Citric Acid 0.15 Unstable
8 0.1 25 mM Citric Acid 0.15 Unstable
9 1 25 mM Citric Acid 0.3 Unstable
10 1 25 mM Citric Acid 0.5 Unstable
11 1 25 mM Acetic Acid 0.1 Unstable
12 1 25 mM Acetic Acid 0.15 Unstable
13 1 25 mM Acetic Acid 0.3 Unstable
14 1 25 mM Acetic Acid 0.5 Unstable
Table 1 Summary of Experimental
Runs. All Experiments Were
Performed at pH 3.0
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Fig. 2 Time evolutions of the average hydrodynamic radius, measured
on-line by the in-situ DLS, for the 1 g/L mAb solution in 25 mM citric
acid buffer at pH 3.0 and different salt contrentations: 0 M (○), 0.1 M
(■), 0.15 M (▲), 0.3 M (●), 0.5 M (>) (Runs 4, 5, 6, 9 and 10 in
Table I).
Antibody Stability in Downstream Processing 1887
tion extent measured by DLS in Fig. 2, indicating that
antibody aggregation and change in secondary structure
occur simultaneously.
In the case of the acetic acid buffer, the observed
aggregation behavior and changes in the secondary
structure for the experimental runs 11 to 14 in Table I
are very similar to those shown above in the case of the
citric acid buffer. Thus, for brevity, the data are not shown,
but the conclusions reached above are also valid for the
acetic acid buffer. On the other hand, this is not the case
for the phosphate buffer where, as shown in Fig. 1b, no
aggregation occurs.
Oligomer Distribution
Samples at different incubation times were taken and
analyzed by SEC and FFF. Examples of the obtained
oligomer distribution are shown in Fig. 4, corresponding to
run 6 in Table I. The distributions obtained from the two
techniques are consistent (note that in FFF larger species
elute after smaller ones, while in SEC they elute in opposite
order). At time = 0, only the monomers and a small
(negligible) fraction of dimers are present. After 3 h
incubation, a sharp decrease in the monomer concentration
and formation of a significant quantity of dimers can be
observed. However, after the first few hours, both the FFF
and SEC chromatograms show that the concentrations of
both monomers and dimers vary very slowly, which is in
good agreement with the DLS data in Fig. 1 and the CD
spectra in Fig. 3b.
In the FFF chromatograms in Fig. 4a the dimer peaks
are asymmetrical and not well separated from the peaks of
trimers and larger species, while the separation is much
more clear in the SEC chromatograms. Nevertheless, a
clear shoulder around the elution time of 15 min can be
observed, representing proper separation between dimers
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Fig. 3 (a) CD spectra for the 1 g/L mAb soltuion in 25 mM citric buffer at
pH 3.0, after 1 day incubation at different salt contrentations: 0 M (1),
0.1 M (2), 0.15 M (3), 0.3 M (4), 0.5 M (5); (b) CD spectra for Case 3 in
(a), measured at different aggregation times: 0 min (1), 10 min (2), 30 min
(3), 50 min (4), 90 min (5), 22 h (6), 48 h (7).
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Fig. 4 (a) FFF chromatograms at different times along the aggregation for
run 6 in Table I; (b) SEC chromatograms at different times for the same
system in (a).
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and trimers. From both the SEC and FFF chromatograms,
the mass fractions of each species can be evaluated based
on the ratio of the area under the corresponding peak and
the total area. The underlying assumption of such approach
is that the absorbance capacity of the oligomers depends
linearly on their size, i.e., a dimer absorbs twice as a
monomer, a trimer three times, and so forth. As a
confirmation of this assumption, in all the experimental
runs the total area remained constant along the aggregation
time, in both SEC and FFF techniques.
It is known that both SEC and FFF can be affected by
several parameters during the analysis, such as interactions
between proteins and the stationary phase, dilution effect of
the injected sample, shear-induced aggregation during the
focus mode of FFF, etc. Thus, it is important to check the
reliability of the obtained distributions. Moreover, compar-
ing the results from different techniques can give informa-
tion about the strength of the formed aggregates and their
reversibility. For example, weakly aggregated oligomers
would be destroyed easily upon dilution during the SEC or
FFF analysis, and the obtained distributions would be
inconsistent with the on-line DLS measurements. To verify
this, we have coupled an on-line DLS system (Wyatt,
Dernbach, DE) with the SEC column, so as to estimate the
hydrodynamic radius, Rh, of dimer and trimer, which were
found to be equal to 7.3 and 9.7 nm, respectively. These
values were then used to calculate the time evolution of the
Z-average hydrodynamic radius of the same system based
on the following well-known relationship (31):
hRhi ¼
PN
1 niðtÞ  i2
PN
1
niðtÞi2
Rh;i
ð1Þ
where i is mass of the oligomer (i.e., the number of the
monomeric mAbs forming the oligomer), while ni and Rh,i
are the number concentration and the hydrodynamic
radius of the oligomer with mass i, respectively. In
particular, in the 〈Rh〉 computations using Eq. 1 for each
corresponding system, we have applied the oligomer
distributions ni that are determined from the analyses of
the SEC and FFF techniques, respectively. In Fig. 5, we
have compared such computed time evolutions of 〈Rh〉 to
those measured directly on-line by the in-situ DLS tech-
nique, in the cases of run 6 and run 9 in Table I. It can be
seen that the agreement between the three techniques is
very good. Therefore, the obtained oligomer distributions
from the SEC and FFF techniques are reliable and reflect
the true oligomer distributions in the system. Moreover,
these results indicate that the oligomers formed during
aggregation are strong enough to survive during the SEC
and FFF fractionation processes.
Furthermore, we have also investigated the long-term
reversibility of the aggregation process. To this aim, we
have collected two samples after 4 h incubation in the case
of run 7 in Table I: one sample was immediately analyzed
by SEC, while another was diluted ten-fold in a salt-free
citric acid buffer, so as to alter the equilibrium, and
analyzed by SEC after 1 h and after 48 h. The results,
shown in Fig. 6, indicate that aggregation is indeed
reversible, and the monomers can be recovered by dilution
in a salt-free buffer. It should be pointed out, however, that
further investigations are required to understand whether
the recovered monomers have the original secondary
structure or keep the same structure as in the oligomers.
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Fig. 5 Time evolutions of the average hydrodynamic radius measured
on-line by the in-situ DLS for runs 6 and 9 in Table I, compared with
those reconstructed from the oligomer distribution data obtained from FFF
and SEC techniques. Run 6: DLS (■), SEC (○), FFF (q); Run 9: DLS (●),
SEC (□), FFF (>).
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Fig. 6 Distributions of the oligomers determined from the SEC
technique for (a) sample from run 7 in Table I after 4 h incubation, (b)
the same as (a) but diluted to 1 g/L mAb concentration in 25 mM citric
acid buffer at pH 3.0 without adding salt and the analysis performed after
1 h, and (c) the same as (b) but the analysis performed after 48 h.
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DISCUSSION
Kinetic Modelling of the Oligomer Formation
Protein aggregation induced by conformational changes is
commonly described by the Lumry-Eyring model, devel-
oped in 1954 (23). According to this model, a native protein
unfolds in a reversible way into an unfolded state which
then aggregates irreversibly. Several recent studies pub-
lished in the literature showed that not only the completely
unfolded species but also different types of intermediates
(near native (32,33) or partly folded (34,35)) can be the
aggregation-prone form of the monomeric species.
In the present work, following the approach of Roberts
(24), we modify the Lumry-Eyring model to describe the
mAb aggregation process, by taking into account the
reversibility of each step. The main assumptions involved
in the model are the following:
– A unique reactive intermediate prone to aggregation is
present, indicated as I. With respect to the aggregation
process, the intermediate (I ) and native (N ) species can
reach thermodynamic equilibrium instantaneously,
which can be described through the equilibrium
constant Keq ¼ kunf =kfold .
– Two I species can aggregate to form a dimer (D).
Larger oligomers are formed only by subsequent
addiction of an I unit, while aggregation between two
oligomers has been neglected.
– Since the observed oligomers larger than trimer are
negligible, trimers (T ) have been considered as the
largest species present in the system.
– All the aggregation steps have been considered reversible
and characterized by intrinsic forward and backward
rate constants. Note that reversibility was not taken into
account in the original Lumry-Eyring model, but it has
been observed in several studies (25,36).
The resulting reaction scheme is shown in Fig. 7, based
on which the following mass balances can be derived:
d N½ 
dt
¼ kunf N½  þ kfold I½  ð2Þ
d I½ 
dt
¼ kunf N½   kfold I½   2k1 I½ 2 þ 2k1 D½   k2 I½  D½  þ k2 T½ 
ð3Þ
d D½ 
dt
¼ k1 I½ 2  k1 D½   k2 I½  D½  þ k2 T½  ð4Þ
d T½ 
dt
¼ k2 I½  D½   k2 T½  ð5Þ
where [N ], [I], [D] and [T ] are the molar concentrations of
native mAb, intermediate species prone to aggregation,
dimers and trimers, respectively; k1 and k2 are the rate
constants for the dimer and trimer formation, respectively;
and k−1 and k−2 are the rate constants for the corresponding
backward reactions.
For the experimental techniques applied in this work, it
is impossible to distinguish between the N and I species.
The experimentally measurable quantity is in fact only the
total monomer concentration M½  ¼ N½  þ I½ , whose mass
of the total monomer concentration f ; ½I  ¼ f  ½M ,
where f ¼ Keq=ð1þ KeqÞ. Then, Eqs. 2 to 5 can be re-
written using only experimentally measurable quantities as
follows:
d M½ 
dt
¼ 2k1;app M½ 2 þ 2k1 D½   k2;app M½  D½  þ k2 T½  ð6Þ
d D½ 
dt
¼ k1;app M½ 2  k1 D½   k2;app M½  D½  þ k2 T½  ð7Þ
d T½ 
dt
¼ k2;app M½  D½   k2 T½  ð8Þ
where the apparent rate constants, k1;app ¼ f 2  k1 and
k2;app ¼ f  k2, have been introduced. It is worth noting
that such apparent rate constants are composed of two
terms describing the two main aspects of the process: the
conformational stability behavior of the macromolecule
(represented by f) and the kinetic colloidal stability of the
solution (represented by the intrinsic kinetic constants k1
and k2). The two aspects are intrinsically interconnected,
and their individual contribution to the aggregation process
cannot be distinguished.
The k1,app value can be evaluated experimentally from
the early stage of the aggregation where the only species
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Fig. 7 Scheme of the aggregation process based on a modified Lumnry-
Eyring model.
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present in the system are monomers and dimers, while
trimers are negligible. Then, at time t→0, Eq. 6 reduces to
d M½ 
dt




0
¼ 2k1;app  M½ 2; ð9Þ
which can be easily integrated:
1
M½  
1
M0½  ¼ 2k1;app  t; ð10Þ
where [M0] is the given concentration of total monomers at
t=0. Thus, the plot of 1/[M]-1/[M0] versus t should be a
straight line whose slope gives k1,app. Indeed, this was
verified, as shown in Fig. 8, for experimental runs 6, 9 and
10 in Table I.
The other three unknown kinetic parameters, k2,app, k−1
and k−2, have been estimated by solving Eqs. 6 to 8 and
fitting the experimental data, minimizing an error function.
Applying such procedure, it is possible to estimate with
uniqueness the kinetic constant k−1 and the equilibrium
constants K2;eq ¼ k2;app=k2, for the formation of trimers.
Details about the fitting procedure can be found in the
Supplementary material. The summary of the estimated
parameter values is reported in Table II.
It is worth noting that based on the physicochemical
meaning of the kinetic rate constants they are not expected
to depend on the mAb concentration but to do so for NaCl.
Therefore, we fit run 6 in Fig. 9a and then, with the same
kinetic parameters, we predict runs 7 and 8 in Fig. 9b (for
the sake of simplicity, only time evolutions of the residual
monomers are reported). In Fig. 10a the time evolutions of
the residual monomers at different salt concentrations fitted
by the model using the kinetic parameters in Table II are
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Fig. 8 Monomer conversion, plotted in the form of 1= M½   1= M0½ 
(according to Eq. 10), versus time for the 1 g/L mAb solution in 25 mM
citric acid buffer at pH 3.0 and different salt concentrations: 0.15 M (▲),
0.3 M (●), 0.5 M (>) (Runs 6, 9 and 10 in Table I). Continouos lines
represent fitting to experimental data.
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Fig. 9 Comparison between model predictions (continuous curves) and
experimental data (symbols). (a) Time evolutions of monomer (○), dimer
(□) and trimer (>) mass fractions for run 6 in Table I; (b) effect of the mAb
concentration on the kinetics: 0.1 g/L (>), 1 g/L (○), 10 g/L (□) (i.e., Runs
7, 6 and 8 in Table I, respectively).
Table II Values of the Rate Constants Corresponding to the Kinetic
Scheme in Fig. 7 Estimated at Different Salt Concentrations
NaCl Conc k1,app k−1 K2;eq ¼ k2;app=k2
[mol/L] [L·mol−1·s−1] [1·s−1] [L·mol−1]
0.1 5.3 1.50·10−4 4.29·104
0.15 15.5 1.37·10−4 1.05·105
0.3 30 3.59·10−5 1.54·107
0.5 32.5 3.02·10−5 5.49·107
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compared to the experimental results. Again, good agree-
ment has been obtained. It is therefore concluded that the
modified Lumry-Eyring model can well represent the
aggregation process of the considered mAb systems.
In addition, to better understand the salt effect on the
oligomer formation, we plot the equilibrium constants,
K1;eq ¼ k1;app=k1 and K2;eq ¼ k2;app=k2, for the formation
of dimers and trimers, respectively, as a function of salt
concentration (Fig. 10b and c). Both K1,eq and K2,eq increase
monotonically as the salt concentration increases. The data
in Table II show that such a trend results from the
monotonic increase in the forward reactions and the
decrease in the backward reactions as a function of the salt
concentration. Although at very low salt concentrations the
salt effect may be reasonably explained by protein charge
screening by the salt ions as described by the classical DLVO
theory (37,38), for the salt concentration investigated in this
work (0.1–0.5 M), additional salt effects on system thermo-
dynamics and solvation effects (salting-out) must be considered
(4). More specifically, the changes in the system thermody-
namics with adding salt are mostly related to anion binding,
which reduces electrostatic repulsive forces both intra- and
inter-molecularly (39), with two consequences: (1) changes in
the secondary structure of the mAb (most likely, the
formation of a more reactive intermediate I in the scheme
in Fig. 7 is favored), and (2) increase in the possibility for
hydrophobic surface patches of two aggregating proteins to
come closer. Salting-out effect is related to attractive protein-
protein interaction arising from preferential exclusion of the
salt from protein-surface and consequent increase of protein-
surface free energy (40). Evidently, all these effects go beyond
charge screening and DLVO model and are not separable.
Nevertheless, on the basis of the analysis above, we can
conclude that addition of the salt has two main overall
consequences: (1) promoting aggregation (i.e., increasing .k1,
app in Table II), and (2) increasing the aggregation-bond
strength, thus decreasing the backward reaction rate (k−1).
These, in turn, lead to a shift of the equilibria in Fig. 7
towards oligomers formation.
CONCLUSIONS
In the present work, the aggregation (stability) behavior of
monoclonal antibody (mAb) solutions has been investigated
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Fig. 10 (a) Fitting of the salt effect on the aggregation kinetics by the
model (continuous curves), compared with the experimental data
(symbols): 0.1 M (○), 0.15 M (□), 0.3 M (>), 0.5 M (q) (i.e., runs 5, 6,
9 and 10 in Table I, respectively); (b) the estimated kinetic parameters for
dimer formation in Table II, plotted in the form of K1;eq ¼ k1;app=k1 as a
function of the salt concentration, and (c) the same as (b) but for trimer
formation, K2;eq ¼ k2;app=k2.
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under industrial-relevant conditions, typically encountered
during purification through protein A chromatography, i.e.,
acidic conditions and presence of salt (NaCl) in the
concentration range of 0.1–0.5 M. The aggregation was
followed on-line by dynamic light scattering (DLS), and the
oligomer distributions were analyzed off-line through both
FFF (field flow fractionations) and SEC (size exclusion
chromatography) separation techniques.
It is found that the main parameters affecting mAb
aggregation are pH and salt concentration. At pH below
4.0 and in the presence of salt, the antibodies self-associate
(aggregate) progressively with time to form small oligomers
(e.g., dimers and trimers). The aggregation is accompanied
by an increase in the content of the secondary β–sheet
structure of the mAb. A lag-phase that is commonly
encountered in the aggregation of other similar proteins is
not observed here. Even after 1 month, neither macro-
scopic changes of the solution or precipitation of large
aggregates can be observed. The monomers can be
recovered from the oligomers by dilution in salt-free
solutions, indicating that the aggregates are reversible.
Both the FFF and SEC techniques have been successfully
applied to measure the oligomer distributions (i.e., mono-
mer, dimer and trimer), and the results between the two
techniques are in good agreement. To support the
reliability of the obtained oligomer distributions, we have
applied them to reconstruct the time evolution of the
average hydrodynamic radius and compared the obtained
values to the on-line DLS measurements, and good
agreement has been obtained. Thus, the approach applied
in this work represents an example of oligomer determina-
tion, which may be applied in other protein-aggregation
systems to obtain important information about oligomer
distribution and reversibility.
The aggregation kinetic data have been interpreted using
a modified Lumry-Eyring model, where reversibility has
been introduced into the reaction scheme. The key assump-
tion of the model is an initial reversible conformational
change resulting in an aggregation-prone intermediate I. It
is found that with properly estimated parameters, the
proposed kinetic model can well predict the time evolution
of all the oligomers determined from the FFF and SEC
techniques and properly account for the effect of the mAb
and salt concentrations on the aggregation kinetics.
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